ABSTRACT -Diabetic cardiomyopathy can progress toward overt heart failure with increased mortali--amine (vitamin B 1 ) is an indispensable coenzyme and required at intracellular glucose metabolism. In this -zotocin-induced diabetic rat. Normal control and diabetic rats were studied for 2 weeks with and without thiamine, and followings were analyzed; plasma biochemicals (total cholesterol and triglycerides), mor--tissue growth factor) as well as and matrix metalloproteinase activity were investigated. Thiamine replemetalloproteinase activity in the heart of diabetic rats. O the left ventricular of diabetic rats compared to control rats, which was decreased by thiamine adminisby suppression of hexosamine biosynthesis pathway.
INTRODUCTION
Mega clinical studies, i.e., Framingham study, studies of left ventricular dysfunction (SOLVD), heart outcome prevention evaluation study (HOPE) and cardiovascular health study (CHS) report that diabetes is a major risk factor of heart failure (William et al., 1974; Ho et al., 1993; Shindler et al., 1996; Bertoni et al., 2003; Piccini et al., 2004) . Although cardiac failure in diabetes is mostly due to coronary artery disease relevant ischemic heart disease, the incidence of heart failure in diabetes independent of atherosclerotic coronary lesion is speculated to be 4 to 5 times higher than in normal people. Rubler et al. (1972) propounded the concept of diabetic cardiac failure without coronary lesion as diabetic cardiomyopathy, which was accompanied by systolic and diastolic failure due to diabetes per se. The high incidence and poor prognosis of heart failure in diabetic patients have been linked in part to the presence of an underlying diabetic cardiomyopathy characterized by myocelet al., 1980) . Experimentally induced diabetes models cause changes in myocardial cellular calcium transport and contractile proteins, which result in subclinical systolic and diastolic dysfunction (Ganguly et al., 1983; Giacomelli and Wiener, 1979) . The increased myocardial collagen content associated with diabetic cardiomyopathy further worsens diastolic dysfunction (Poirier et al., 2001) .
Among the possible mechanisms of glucose-induced cellular damage and phenotype changes, four hypotheses have been widely accepted and clinical trials established polyol pathway; (2) increased formation of advanced glycation end (AGE) product; (3) protein kinase C (PKC) biosynthesis pathway (HBP) (Beltramo et al., 2008) . Activation of PKC isoforms leads to endothelial dysfunction by activation of NADPH oxidase, enhanced vascular permeability through upregulation of vascular endothelial growth factor, and thrombosis by increasing plasminogen activator inhibitor (PAI)-1 levels (Williams and Nadler, 2007) . The activation of the HBP also contributes to the mechanisms of diabetes-induced cellular damages. Stimulatory protein 1 (Sp1), one of the transcriptional factors, can be O O-GlcNAc) enzymatic glycosylated. O-GlcNAc enzymatic glycosylation (O-GlcNAcylation) of Sp1 increased Sp1 transactivation and Sp1-dependent expression of both transforming et al., 2000; Verrecchia et al., 2001) .
Thiamine is an indispensable coenzyme and required at several stages of anabolic and catabolic intermediary metabolism such as intracellular glucose metabolism (glycolysis, Krebs cycle, pentose-phosphate cycle). Although diabetic subjects usually do not man--ciency, it was observed that diabetic subjects tend to have lower blood thiamine concentrations than healthy controls, together with a reduced erythrocyte transketolase activity (Saito et al., 1987; Valerio et al., 1999; Jermendy, 2006) and an increased thiamine renal clearance (Thornalley et al., 2007) . Recently, high-dose benfotiamine, a lipophilic derivative of thiamine, has been shown to inhibit increase of HBP, diacylglycerol (DAG) pathway and AGE pathway under the hyperglycemia state, accompanied with the prevention of the pathogenesis of diabetic nephropathy and retinopathy and the delay of the diabetes-related complications (Hammes et al., 2003) . In the streptozotocin (STZ) rat model of due to PKC activation, reported to be inhibited by thiamine administration (Koya et al., 1997 ; Babaei-Jadidi et al (Melhem et al., 2001) . Tanaka et al. (2007) have observed that thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR through rectifying the balance of glucose oxidation to its cellular entry. On the supposition that diabetes might be considered a thia--tive to the increased requirements deriving from acceleret al., 2008), we hypothesize that (1) thiamine repletion could into the major pathway of glucose metabolism rather than into the minor pathway, and, in turn, (2) it could decrease detrimental metabolic products in each minor pathway.
In this study, we focus on heart failure, especially on cardiac fibrosis, and investigated the following issues, -ondarily the biological and histological analysis of cardiinduced diabetic rats by thiamine administration.
MATERIALS AND METHODS

Chemicals
Thiamine hydrochloride was supplied by Kishida Chemical Co., Ltd. (Osaka, Japan). Streptozotocin was purchased from Wako Pure Chemical Industries, Japan. Glu Test Sensor was supplied by Sanwa Chemical (Nagoya, Japan). Antibodies used were as follows; anti-O-linked glycosylation antibody (RL-2) from the anti-mouse immunoglobulin and peroxide-conjugated mouse immunoglobulin (H&L, horseradish peroxidaseSirius red F3BA was supplied by Polysciences, Inc. (Warhighest purity available (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Animals
Male Wistar-Kyoto rats (6 weeks of age) were used in all experiments. They were the progeny of rats obtained from the Charles River (Kanagawa, Japan) and were maintained in the central animal facility of our university. The animals were provided with a commercial diet and water ad libitum under temperature-, humidity-, and lighting-controlled conditions (22 ± 2°, 55 ± 5%, and a 12:12-hr light-dark cycle, respectively). Experimental protocols and animal care methods in the experiments were approved by the Experimental Animal Research Commit-blood samples. Only rats with blood glucose levels > 300 mg/dl 3 days after STZ injection were used. Rats treated with a single intraperitoneal injection of vehicle were used as controls. Thiamine was given by water containing 0.2% thiamine.
Rats were placed in one of four study groups as follows; group 1, untreated nondiabetic controls; group 2, untreated diabetic rats; group 3, diabetic rats supplemented with thiamine; group 4, nondiabetic controls supplemented with thiamine. Groups 1 and 2, untreated groups, were freely accessed to tap water. Groups 3 and 4, thiamine treated groups, were freely accessed to the tap water containing 0.2% thiamine. Groups 3 and 4 were started with the supplementation of thiamine 3 days before, and maintained to 15 days after STZ and vehicle injection.
Measurements of blood pressure and Echocardiographic analysis
Heart rate and systolic blood pressure were measured by a tail-cuff system (BP98A, Softron) in conscious animals.
Fifteen days after STZ and vehicle treatments, echocardiography was performed on lightly anaesthetized rats (1-2% isoflurane, with spontaneous ventilation). Twodimensional guided M-mode echocardiography was performed with the use of an echocardiogram equipped with a 10-MHz transducer (Vivid 7 echocardiographic scanner, GE Medical Systems, Horten, Norway). The heart was imaged in a two-dimensional mode in a parasternal shortaxis view with a depth setting of 2 cm. From this view, an M-mode cursor was positioned perpendicular to the interventricular septum and posterior wall of the left ventricle at the level of the papillary muscles. An M-mode image was obtained at a sweep speed of 100 mm/sec. Left ventricular (LV) ejection fraction (EF), LV enddiastolic dimension (D d ), LV end-systolic dimension (D s ) and LV fractional shortening (FS) were measured. The LV systolic function was assessed using the LV ejection fraction (EF).
At the end of the echocardiographic analysis, rats were killed by over-doses of pentobarbital and blood was withdrawn by cardiac puncture. The plasma was immediately biochemical measurements.
The heart and kidney were removed and weighted. Organ weight was normalized by tibia length. Heart was immunohistochemical and Sirius red staining.
Measurements of blood parameters
Total plasma cholesterol and triglycerides were assayed enzymatically using the T-Cho E and the TG E commercial kits, respectively, purchased from Wako (Osaka, Japan).
Measurement of thiamine levels in plasma and red blood cells
Thiamine levels were determined by the modification described by Marszall et al. (2005) and Lebiedzinska et al. (2007) , as follows. Phosphorylated thiamine metabolites were dephosphorylated with diastase and total thiamine status was determined by high-performance liq- (post-column derivatisation to thiochromes). To remove -cyte hemolysate) was treated with 1 ml of 10% trichloroacetic acid (TCA) and then centrifuged at 5,000 x g at 4°C 2% diastase solution followed by incubation for 10 hr at Japan), connected to a Simadzu HPLC system (SCL-10A) (excitation and emission wavelength 375 and 440 nm, respectively). The mobile phase (0.8 ml/min) consisted of methanol and phosphate buffer (0.01 mol/l sodium dihydrogenphosphate, 0.15 mol/l sodium perchlorate (pH 2.2) -chromes in reaction coil (5 m x 0.33 mm) with 15% (w/v) K3(Fe(CN)6) and 15% (w/v) NaOH (0.4 ml/min).
of a standard curve constructed with known amounts of thiamine (Sigma). The calibration curve was linear (r 2 = 0.998) over thiamine concentrations ranging from 4 to 10-100 nM.
Assessment of total collagen contents with Sirius red staining
Total collagen content of the Sirius Red (Polyscience, -ius Red stained area was assessed using computer softas the right and left ventricle.
Assessment of O-glycosylation with immunohistochemistry
oclonal RL-2 antibody was used as a primary antibody (1:100; overnight at 37°C), followed by a biotinylated goat anti-mouse antibody (1:200) for streptavidin-biotin complex peroxidase staining. Detection was carried out with the use of peroxidase as label and 3,3' diaminobenzidine as substrate. Negative controls were performed by omitting the primary antibody. using computer software scion image beta 4.03 (scion Immunoreactive area was calculated as the area occupied by positive area divided by the total tissue area within the same microscopical view.
Assessment of metalloprotease activity by gelatin zymography
Metalloproteinase 2 (MMP2) activity was determined in the LV tissue by zymography. LV (100 mg) tissues cacodylic acid, 0.15 mol/l NaCl, 20 mmol/l CaCl 2 , 1.5 mmol/l NaN 3 2 Total homogenates were centrifuged at 15,000 x g for 40 min at 4°C. The supernatant was mixed to sample buffer (pH6.8 Tris-HCl, 10% glycerol, 2% sodium dodecyl sulfate (SDS), 0.0025% bromphenol blue). The proteins (60 -mide gel containing 0.1% gelatin and 0.1% SDS.
After electrophoretical separation with 125V constant voltage, gels were washed in renaturing buffer (2.5% TrimM Tris-HCl, 5 mM CaCl 2 , 50 mM NaCl, 0.05% Brij-35, pH7.6) for 3 overnights at 37°C. Then, gels were stained in 0.1% coomasie blue R-250 for 30 min and destained in 7% acetic acid and 7% methanol in water. MMP2 activities were visualized as clear areas due to lysis of gelatin by the size-fractionated banding pattern densitometrically by Multi gauge (Fuji Film, Japan). Gelatinase zymogra--ada) used as positive controls.
RNA preparation and real-time PCR analysis
Left ventricle was cut into 5 mm 3 in RNAlater (Ambion) until RNA preparation. Total RNA was extracted using RNeasy Fibrous Tissue Mini-Kits (Qiagen). The purity and concentration were determined by measuring the optical density at 260 and 280 nm before use. The optical density ratio at 260/280 ranged from 1.8 RNA was reverse transcribed into cDNA using Transcriptor First Strand cDNA Synthesis Kit (Roche). Each realtime PCR (RT-PCR) reaction contained 25 ng of cDNA, -Primer Express Software (Applied Biosystems, Forster sequences are described in Table 1 . The cDNA was denatured at 95°C for 10 min, followed by 45 cycles at 95°C for 10 sec, 60°C for 5 sec, and 65°C for 15 sec followed by 40°C for 30 sec. Each sample was performed in triplicate on a LightCycler and was analyzed using LightCycler3 Front software (Roche). The relative mRNA levels were calculated by the comparative threshold cycle meth-
Statistical analysis
Results are expressed as means ± S.E. The significance of the differences between the groups was analyzed by Tukey-Kramer test after analysis of variance. P values
RESULTS
Plasma glucose levels in STZ-induced diabetic rats, and effects of thiamine repletion
Plasma glucose levels, determined by the glucose oxidase (GOD) method, were remarkably higher in STZ-administered rats compared with normal contreatment replete with thiamine; p < 0.01, control vs STZ-treatment and STZ-treatment replete with thiamine; -mine) (Fig. 2) . Thiamine repletion did not have an effect on plasma glucose levels in all groups, as reported by Babaei-Jadidi et al. (2003) .
Plasma and red blood cell thiamine levels in STZ-induced diabetic rats, and effects of thiamine repletion STZ treatment results in prominent decreases in plasma and red blood cell thiamine concentration (plasma; STZ-treatment, p < 0.01) (Figs. 3A and 3B ), in accordance with the result of Babaei-Jadidi et al. (2003) . Thiamine repletion counteracts the STZ-induced thiamine and 3B). In control rats, no observable changes were noted in thiamine levels in both plasma and red blood cell. Effect of thiamine on heart rate, blood pressure and lipids levels in STZ-induced diabetic rats Table 2 shows mean heart rate, systolic blood pressure, plasma cholesterol and triglycerides 15 days after STZ injection. STZ-treatment did not have an effect on -in STZ-treatment, p < 0.05). Thiamine did not rescue the bpm in STZ-treatment replete with thiamine) (Table 2) . Plasma triglycerides levels were increased in STZ -amine repletion significantly improved STZ-induced mg/dl in STZ-treatment replete with thiamine; p < 0.05, STZ-treatment vs STZ-treatment replete with thiamine). Plasma total cholesterol levels were also increased in STZtreated rats but were not altered by the thiamine treatment treatment replete with thiamine) ( Table 2) .
Effect of thiamine on cardiac function in STZ-induced diabetic rats
Echocardiographic analysis revealed the decrease of fractional shortening in STZ-induced diabetic rats treatment, p < 0.05), which was moderately ameliorated replete with thiamine), but failed to reach significance (Table 3) . On the other hand, no observable changes were found in LV ejection fraction, LV end-diastolic diameter and LV end-systolic diameter (Table 3) .
Effect of thiamine on mRNA abundance of brain natriuretic peptide (BNP) in STZ-induced diabetic rats LV
BNP is known to regenerate in failing heart and has been used as a marker for heart failure. Quantitative realabundance in the LV of STZ-treated rats compared with -tive mRNA levels in STZ-treatment, p < 0.01), which was almost completely rescued by thiamine repletion replete with thiamine; p < 0.01, STZ-treatment vs STZtreatment replete with thiamine) (Fig. 4) .
Effect of thiamine on organ weight in STZ-induced diabetic rats
Tibial lengths were comparable in each experimental group, suggesting no growth retardation in STZ-induced diabetic rats and thiamine repletion during 15 days of observation frame. The weights of whole heart, ventri--g/tibial length (10 -2 -ial length (10 -2 ) in STZ-treatment, p < 0.01; ventricu--2 ) in control and -2 ) in STZ-treatment, p -2 ) in control -2 ) in STZ-treatment, p < 0.01 (Table 4) , and thiamine repletion, no statistical significance but partially, rescued this atrophic change -2 ); ventricular; -2 -ial length (10 -2 ) in STZ-treatment replete with thiamine) (Table 4) . No observable changes were found in kidney weight of STZ-induced diabetic rats.
STZ-induced diabetic rats
Fibrosis is a characteristic of diabetic cardiomyopaSirius red staining, with representative pictures shown in -ital image, was markedly increased in STZ-induced diabetic rats compared with control rats, which was signif- STZ-treatment replete with thiamine; p < 0.01, control vs STZ-treatment; p < 0.01, STZ-treatment vs STZ-treatment replete with thiamine) (Fig. 5E ).
Effect of thiamine on mRNA abundance relevant -onstrated by Sirius red staining motivated us to evaluate ---din, fibronectin, PAI-1 and CTGF mRNA abundance --cantly suppressed by thiamine repletion (thrombospondtreatment replete with thiamine, p < 0.01; STZ-treatment vs STZ-treatment replete with thiamine) (Fig. 6) , except for CTGF. CTGF mRNA abundance in the LV of STZinduced diabetic rats tended to decrease by thiamine
Effect of thiamine on MMP2 activity in LV of STZ-induce diabetic rats
Collagen deposition was regulated by synthesis and degradation of collagen. We next examined whether STZ-induced diabetic rats by gelatin zymography. The (Fig. 7) .
Protein O-glycosylation (RL-2) in LV of STZ-induced diabetic rats and effect of thiamine repletion The activation of the HBP is known to contribute to the mechanisms to the diabetes-induced cellular damages. Sp1, one of transcriptional factors, can be O-GlcNAcylated. O-GlcNAcylation of Sp1 increased Sp1 transactivation and Sp1-dependent et al., 2000; Verrecchia et al., 2001) .
Immunoreactivity was observed in cytosol and nucleus with the RL-2 antibody, which is consistent with previous reports that nuclear and cytosolic proteins are glycosylated by O-GlcNAc transferase (Kreppel et al., 1997; Lubas et al., 1997) . RL-2-immunoreactivity was enhanced in the hearts of STZ-induced diabetic rats compared with that of control rats, representative pictures shown in Figs. 8A-- (E) Vol. 33 No. 4 ly higher in rats with STZ-induced diabetes compared to in STZ-treatment; p < 0.01, control vs STZ-treatment) (Fig. 8F) . Thiamine treatment prevented the increases of immunoreactivity in STZ-induced diabetic rats < 0.01, STZ-treatment vs STZ-treatment replete with thiamine) (Fig. 8F) .
DISCUSSION
ma glucose and triglyceride levels, and moderate but sigderangement in the glucose and lipid metabolism. In addiand red blood cells, supporting the concept that diabetes et al reduction of triglyceride levels. On the other hand any thiamine treatment as reported by others (Babaei-Jadidi et al., 2003; Ceylan-Isik et al., 2006; Wu and Ren, 2006) . Dysfunction of both contraction and relaxation is regarded as a trait of diabetic cardiomyopathy (Hofmann et al., 1995; Ren and Ceylan-Isik, 2004; Wold et al., 2005) . In our study hemodynamic parameters evaluated with echocardiography revealed only marginal but sigbiochemical and morphological analyses demonstrated increased BNP, a biochemical surrogate index for heart failure, mRNA abundance and increased collagen deposit in LV tissue. Several mechanisms have been postulated for the mechanical dysfunction in diabetic hearts.
Evidence from experimental models of diabetic cardiomysubstrate of diabetic cardiomyopathy (Riva et al., 1998; Tschöpe et al., LV stiffness and decreased ventricular wall compliance, resulting in systolic and in particular diastolic dysfunction. Thiamine repletion countered these biochemical and morphological disorders produced by STZ diabetes; the reduction of BNP mRNA abundance and reduction of collagen deposit in LV.
Diabetic subjects are predisposed to have lower blood thiamine concentrations than healthy controls, accompanying a reduced erythrocyte transketolase activity (Saito et al. 1987; Valerio et al., 1999; Jermendy, 2006) . Thia--nize due to lack of typical clinical features, is speculated to be bring out by (1) an increased thiamine renal clearance (Thornalley et al., 2007) , (2) a decreased intestinal absorption and membrane transport of thiamine (Patrini et al., 1996) , and (3) an increased consumption of thiamine caused by an augmented glucose metabolism (Yui et al., 1980; Seligmann et al., 1991) . Additionally, high production of reactive oxygen species (ROS) in diabetes mellitus could oxidize thiamine, with the production of inactive compounds, such as thiochrome and oxydihydrothiochrome (Stepuro et al., 1997; Obrenovich and Monnier, 2003) .
been demonstrated in experimental models of diabetic complications, i.e., retinipathy, nephropathy and cardiomyopathy (Babaei-Jadidi et al., 2003; Hammes et al., 2003; Ceylan-Isik et al., 2006) . Actually high-dose thia- mine therapy is accepted for diabetic peripheral neuropathy in Europe. Water-soluble thiamine is not stored in the body, but rapidly excreted in the urine and must be replenished every 5-6 hr (Greb and Bitsch, 1998) . Although the intestinal thiamine transporter is saturated by relatively low doses of thiamine, there is slow passive diffusion of thiamine at high concentrations (Rindi and Lafarenza, 2000) . Accordingly, we reasoned that freely access of a water containing thiamine could be effective to counteract diabetic complications. The clear-cut mechanisms underlying the pathophysiology of diabetic complications, including cardiopmycondition, glucose enters into cells via insulin-indeEndothelial cells and pericytes are unable to regulate glucose transport, reaching high levels of intracellular glucose concentrations (Kaiser et al., 1993) , in the presence of hyperglycemia. This is probably a rationale of vascular damages generally observed in diabetes mellitus. Increased glucose entry, resulting from hyperglycemia, could exceed the capacity of glucose oxidation, a major pathway of glucose metabolism, and then could orient to a minor pathway of glucose metabolism. Hence, activations of minor pathways have been proposed to potentially contribute to the development of diabetic complications, i.e., activation of DAG pathway with subsequent activation of PKC, activation of the polyol pathway, formation of AGE, increased production of ROS, and activation of the HBP (Du et al., 2000; Brownlee, 2001) . Among these contributors, DAG pathway and HBP potentially impinge various transcriptional factors, i.e., phosphorylation and O-glycosylation. Well-established modulation of gene expression is the phosphorylation of transcriptional factors by PKC, which could be, at least partially, accountable for the abundance of mRNA expression shown in this study, i.e., abundance -bospondin (Daniel et al., 2004 (Daniel et al., , 2007 .
Alternatively, protein O-glycosylation modification could be responsible for the phenotype changes in STZet al., 2005) . O-GlcNAcyla--gle O-GlcNAc molecule to serine or threonine residues, is -ar transport, and cell signaling (Comer and Hart, 1999; Yang et al., 2001; Vosseller et al., 2002; Walgren et al., 2003; Kneass and Marchase, 2005) . Similar to phosphorylation, O-GlcNAc addition by O-linked GlcNAc transferase (OGT), or its removal by N-acetylglucosaminidase (O-GlcNAcase, GCA) is a highly dynamic and reversible process that is susceptible to perturbation under certain pathophysiological circumstances . Sp1, one of transcriptional factors, can be O-GlcNAcylated. O-GlcNAcylation of Sp1 increased Sp1 transactivation and et al., 2000; Verrecchia et al., 2001) .
Thiamine repletion counteracted the STZ-induced cardiac phenotype. Thiamine acts as an indispensable coenzyme for transketolase and for the pyruvate dehydroenzymes which play a fundamental role for intracellular glucose metabolism. Hammes et al. (2003) reported that the lipid-soluble thiamine derivative benfotiamine can inhibit the HBP, the AGE formation pathway and the DAG-PKC pathway, as well as hyperglycemia-associatpathway enzyme transketolase. In this study, unfortunately, we did not address the enzymatic activities involved in glucose metabolism; nevertheless we believe that thiamine repletion re-orients the glucose metabolism from the minor pathway to the major pathway. Interestingly, the counteraction of thiamine against STZ-induced carglucose concentration, as shown in our study and other investigators (Babaei-Jadidi et al., 2003; Ceylan-Isik et al., 2006; Wu and Ren, 2006) . In the therapy of diabetic complications, it is necessary to control not only plasma glucose concentration but also, we believe, intracellular glucose metabolism.
